Американское общество гирудотерапии

Probing intermolecular backbone H-bonding in serine proteinase-protein inhibitor complexes

Research article published in Chemistry & biology (1999)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Разработка лекарственных препаратовLu W et al. · Chemistry & biology, 1999

Abstract

BACKGROUND: Intermolecular backbone H-bonding (N-H.O=C) is a common occurrence at the interface of protein-protein complexes. For instance, the amide NH groups of most residues in the binding loop of eglin c, a potent serine proteinase inhibitor from the leech Hirudo medicinalis, are H-bonded to the carbonyl groups of residues in the target enzyme molecules such as chymotrypsin, elastase and subtilisins. We sought to understand the energetic significance of these highly conserved backbone-backbone H-bonds in the enzyme-inhibitor complexes. RESULTS: We synthesized an array of backbone-engineered ester analogs of eglin c using native chemical ligation to yield five inhibitor proteins each containing a single backbone ester bond from P3 to P2' (i.e. -CONH-to -COO-). The structure at the ligation site (P6-P5) is essentially unaltered as shown by a high-resolution analysis of the subtilisin-BPN'-eglin c complex. The free-energy changes (DeltaDeltaGNH-->O) associated with the binding of ester analogs at P3, P1 and P2' with bovine alpha-chymotrypsin, subtilisin Carlsberg and porcine pancreatic elastase range from 0-4.5 kcal/mol. Most markedly, the NH-->O substitution at P2 not only stabilizes the inhibitor but also enhances binding to the enzymes by as much as 500-fold. CONCLUSIONS: Backbone H-bond contributions are context dependent in the enzyme-eglin c complexes. The interplay of rigidity and adaptability of the binding loop of eglin c seems to play a prominent role in defining the binding action.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, U.S. Gov't, P.H.S.
Indexed MeSH termsAmino Acid SequenceAnimalsCattleChromatography, High Pressure LiquidCrystallography, X-RayHydrogen BondingMacromolecular SubstancesModels, MolecularMolecular Sequence DataProtein BindingProtein ConformationSerine Endopeptidases

Резюме

Intermolecular backbone H-bonding (N-H.O=C) is a common occurrence at the interface of protein-protein complexes.

Почему это важно для гирудотерапии

This study used native chemical ligation to synthesize backbone-engineered ester analogs of eglin c—a potent serine proteinase inhibitor from the leech Hirudo medicinalis—to probe the energetic contributions of intermolecular backbone hydrogen bonds at the enzyme-inhibitor interface. Five ester analogs with single backbone modifications from P3 to P2' were tested against bovine α-chymotrypsin, subtilisin Carlsberg, and porcine pancreatic elastase, revealing context-dependent free-energy changes (0–4.5 kcal/mol) and a remarkable 500-fold binding enhancement from one NH→O substitution at P2. This is directly relevant to ASH's domain as it provides detailed molecular-level insight into the binding mechanism of a leech-derived proteinase inhibitor. The caveat is that this is a purely in vitro structural and biophysical chemistry study with no therapeutic or clinical implications directly addressed; the findings concern basic protein–protein interaction energetics rather than hirudotherapy applications.

Цитирование

Probing intermolecular backbone H-bonding in serine proteinase-protein inhibitor complexes

Lu W et al. · Chemistry & biology, 1999

Связанный клинический контекст

Узнайте, как это исследование связано с клинической практикой

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.